Stefan Bourgeois

1.2k total citations
49 papers, 708 citations indexed

About

Stefan Bourgeois is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Stefan Bourgeois has authored 49 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hepatology, 34 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in Stefan Bourgeois's work include Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (25 papers) and Liver Disease Diagnosis and Treatment (24 papers). Stefan Bourgeois is often cited by papers focused on Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (25 papers) and Liver Disease Diagnosis and Treatment (24 papers). Stefan Bourgeois collaborates with scholars based in Belgium, United States and Netherlands. Stefan Bourgeois's co-authors include Christophe Moreno, Thomas Vanwolleghem, Umesh Shukla, Fabien Zoulim, Oliver Lenz, Lieselot Holvoet, Joris Arts, Raf Bisschops, Jan Tack and Philip Caenepeel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Stefan Bourgeois

48 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan Bourgeois Belgium 11 540 535 124 99 37 49 708
Malte H. Wehmeyer Germany 15 422 0.8× 464 0.9× 178 1.4× 74 0.7× 84 2.3× 39 693
Naveen Gara United States 10 246 0.5× 383 0.7× 69 0.6× 113 1.1× 61 1.6× 16 533
Neelam Mohan India 13 254 0.5× 210 0.4× 85 0.7× 219 2.2× 10 0.3× 48 481
Astrid Kemgang France 7 379 0.7× 408 0.8× 56 0.5× 130 1.3× 28 0.8× 11 573
Zsuzsanna Vitális Hungary 13 289 0.5× 352 0.7× 49 0.4× 109 1.1× 8 0.2× 34 544
Gaia Caccamo Italy 12 487 0.9× 512 1.0× 44 0.4× 50 0.5× 38 1.0× 27 643
J.L. Moya Spain 7 377 0.7× 340 0.6× 93 0.8× 92 0.9× 17 0.5× 9 514
Miriam Cuarterolo Argentina 13 466 0.9× 364 0.7× 61 0.5× 182 1.8× 7 0.2× 28 557
M Chousterman France 13 280 0.5× 273 0.5× 77 0.6× 101 1.0× 8 0.2× 56 540
Tadeusz Wojciech Łapiński Poland 14 252 0.5× 263 0.5× 133 1.1× 58 0.6× 10 0.3× 80 554

Countries citing papers authored by Stefan Bourgeois

Since Specialization
Citations

This map shows the geographic impact of Stefan Bourgeois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Bourgeois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Bourgeois more than expected).

Fields of papers citing papers by Stefan Bourgeois

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Bourgeois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Bourgeois. The network helps show where Stefan Bourgeois may publish in the future.

Co-authorship network of co-authors of Stefan Bourgeois

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Bourgeois. A scholar is included among the top collaborators of Stefan Bourgeois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Bourgeois. Stefan Bourgeois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ho, Erwin, P. Michielsen, Thomas Sersté, et al.. (2025). Severe Liver‐Related Outcomes in Patients With Hepatitis Delta: Results From a Multi‐Ethnic Multicenter Long‐Term Follow‐Up Study. Journal of Viral Hepatitis. 32(2). 1–15. 1 indexed citations
2.
3.
Jacobson, Ira M., Stefan Bourgeois, Paul J. Thuluvath, et al.. (2023). The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. Journal of Viral Hepatitis. 30(5). 448–454. 1 indexed citations
4.
Busschots, Dana, Cécile Kremer, Rob Bielen, et al.. (2021). Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduction Journal. 18(1). 54–54. 3 indexed citations
5.
Hees, Stijn Van, Heng Chi, Bettina E. Hansen, et al.. (2019). Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion. Journal of Viral Hepatitis. 26(6). 766–769. 5 indexed citations
6.
7.
Bourgeois, Stefan, Luc Lasser, Geert Robaeys, et al.. (2019). A multicentre, observational study on demographic and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016.. PubMed. 82(1). 43–52. 2 indexed citations
8.
Bielen, Rob, Stefan Bourgeois, Christophe Moreno, et al.. (2019). Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.. PubMed. 82(3). 379–387. 9 indexed citations
9.
Bielen, Rob, Christophe Moreno, Hans Van Vlierberghe, et al.. (2017). Belgian experience with direct acting antivirals in people who inject drugs. Drug and Alcohol Dependence. 177. 214–220. 19 indexed citations
10.
Bourgeois, Stefan, Yves Horsmans, Frederik Nevens, et al.. (2017). Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrobial Agents and Chemotherapy. 61(12). 6 indexed citations
11.
Degré, Delphine, Thomas Sersté, Luc Lasser, et al.. (2017). Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS ONE. 12(1). e0170933–e0170933. 8 indexed citations
12.
Bourgeois, Stefan, Hans Van Vlierberghe, Christophe Moreno, et al.. (2017). Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterology. 17(1). 26–26. 4 indexed citations
13.
Midgard, Håvard, Behzad Hajarizadeh, Evan B. Cunningham, et al.. (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy. 47. 230–238. 25 indexed citations
14.
Gane, Edward, Edwin DeJesus, Ewa Janczewska, et al.. (2017). Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infectious Diseases. 17(1). 389–389. 1 indexed citations
15.
Verlinden, Wim, Stefan Bourgeois, Luisa Vonghia, et al.. (2016). Liver Fibrosis Evaluation Using Real‐time Shear Wave Elastography in Hepatitis C–Monoinfected and Human Immunodeficiency Virus/Hepatitis C–Coinfected Patients. Journal of Ultrasound in Medicine. 35(6). 1299–1308. 15 indexed citations
16.
Moreno, Christophe, Luc Lasser, Jean Delwaide, et al.. (2015). Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium. Hepatology. 62(1). 746. 3 indexed citations
17.
Feld, Jordan J., Christophe Moreno, Roger Trinh, et al.. (2015). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Journal of Hepatology. 64(2). 301–307. 110 indexed citations
18.
Moreno, Christophe, Christophe Hézode, Patrick Marcellin, et al.. (2015). Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. Journal of Hepatology. 62(5). 1047–1055. 63 indexed citations
19.
Orlent, Hans, Hendrik Reynaert, Stefan Bourgeois, et al.. (2011). IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?. PubMed. 74(2). 317–22. 1 indexed citations
20.
Arts, Joris, Philip Caenepeel, Raf Bisschops, et al.. (2008). Efficacy of the Long-Acting Repeatable Formulation of the Somatostatin Analogue Octreotide in Postoperative Dumping. Clinical Gastroenterology and Hepatology. 7(4). 432–437. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Malte H. Wehmeyer Breakdown of academic impact, for papers by Naveen Gara Breakdown of academic impact, for papers by Neelam Mohan Breakdown of academic impact, for papers by Astrid Kemgang Breakdown of academic impact, for papers by Zsuzsanna Vitális Breakdown of academic impact, for papers by Gaia Caccamo Breakdown of academic impact, for papers by J.L. Moya Breakdown of academic impact, for papers by Miriam Cuarterolo Breakdown of academic impact, for papers by M Chousterman Breakdown of academic impact, for papers by Tadeusz Wojciech Łapiński
Rankless by CCL
2026